Sept 27, 2007 - Biodel Inc. (Nasdaq: BIOD) announced the receipt of a notice of issuance from the United States Patent and Trademark Office (USPTO) for the Company's patent encompassing VIAject(TM) and VIAtab(TM), Biodel's two product candidates in clinical trials......VIAject(TM) is a rapid-acting injectable human insulin intended for meal- time use by patients with Type 1 or Type 2 diabetes...VIAtab(TM) is a sublingual tablet formulation of insulin... Biodel's Press Release -
